Randox Unveils Cardiac Care Technology at Major European Medical Event
RANDOX Laboratories (“Randox”), the Antrim-based independent global diagnostics company, will today unveil a revolutionary new cardiac machine at the world’s largest medical trade fair being held this week in Dusseldorf, Germany.
Crumlin, United Kingdom, November 21, 2009 --(PR.com)-- Randox Laboratories (“Randox”), the Antrim-based independent global diagnostics company, will today unveil a revolutionary new cardiac machine at the world’s largest medical trade fair being held this week in Dusseldorf, Germany.
More than 4,000 exhibitors from almost 70 countries are expected at MEDICA 2009, which gives decision-makers from around the world the opportunity to find out about the latest developments in health technologies.
Randox will use the B2B event as a platform to introduce a new Biochip Analyser that can help save cardiac patient lives by providing rapid diagnosis at the point of care.
The company’s Managing Director Dr Peter Fitzgerald said; “Cardiovascular disease is a progressive and complicated condition, covering a spectrum of symptoms which present differently in many patients.
“The Randox Evidence MultiStat is a groundbreaking new desktop analyser which offers cardiac results within 20 minutes. This innovative technology ensures the accuracy and precision of a commercial laboratory analyser within the A&E department, delivering significant benefits for patients by rapidly identifying risk and enabling accurate clinical decisions.”
Dr Fitzgerald added; “With some biomarkers only detectable six hours after a heart attack, patients presenting with early symptoms are often missed. The Evidence MultiStat has the potential to save lives by giving accurate and timely diagnosis when time is at a premium.”
The Evidence MultiStat is also available now for screening for the use of illegal drugs and has the potential to be used for detecting stroke, cancer, fertility disorders, thyroid disorders and metabolic syndrome, all of which are currently in development. The system is suitable for a variety of patient environments including emergency departments, cardiac units, doctor surgeries, forensic units, rehab units and employee drug screening centres.
###
More than 4,000 exhibitors from almost 70 countries are expected at MEDICA 2009, which gives decision-makers from around the world the opportunity to find out about the latest developments in health technologies.
Randox will use the B2B event as a platform to introduce a new Biochip Analyser that can help save cardiac patient lives by providing rapid diagnosis at the point of care.
The company’s Managing Director Dr Peter Fitzgerald said; “Cardiovascular disease is a progressive and complicated condition, covering a spectrum of symptoms which present differently in many patients.
“The Randox Evidence MultiStat is a groundbreaking new desktop analyser which offers cardiac results within 20 minutes. This innovative technology ensures the accuracy and precision of a commercial laboratory analyser within the A&E department, delivering significant benefits for patients by rapidly identifying risk and enabling accurate clinical decisions.”
Dr Fitzgerald added; “With some biomarkers only detectable six hours after a heart attack, patients presenting with early symptoms are often missed. The Evidence MultiStat has the potential to save lives by giving accurate and timely diagnosis when time is at a premium.”
The Evidence MultiStat is also available now for screening for the use of illegal drugs and has the potential to be used for detecting stroke, cancer, fertility disorders, thyroid disorders and metabolic syndrome, all of which are currently in development. The system is suitable for a variety of patient environments including emergency departments, cardiac units, doctor surgeries, forensic units, rehab units and employee drug screening centres.
###
Contact
Randox Laboratories
Charlotte Jess
02842 8695748
www.randox.com
Charlotte Jess
02842 8695748
www.randox.com
Contact
Categories